Giron-Callejas, Amalia; Garcia-Morales, Claudia; Mendizabal-Burastero, Ricardo; Meza, Rita I.; Sierra, Tomasa; Tapia-Trejo, Daniela; Perez-Garcia, Marissa; Quiroz-Morales, Veronica S.; Paredes, Mayte; Rodriguez, Alizon; Juarez, Sandra I.; Farach, Nasim; Videa, Geraldina; Lara, Bredy; Rodriguez, Edith; Ardon, Elvia; Sajquim, Edgar; Lorenzana, Rolando; Ravasi, Giovanni; Northbrook, Sanny; Reyes-Teran, Gustavo; Avila-Rios, Santiago published the artcile< High level of pre-treatment and acquired HIV drug resistance in Honduras: a nationally representative survey, 2016-17>, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is nigh level pretreatment acquired HIV drug resistance.
Background: Pre-treatment HIV drug resistance (HIVDR) to NNRTIs has consistently increased in low-/middle-income countries during the last decade. Objectives: To estimate the prevalence of pre-treatment HIVDR and acquired HIVDR among persons living with HIV (PLHIV) on ART for 12 ± 3 mo (ADR12) and ≥48 mo (ADR48) in Honduras. Patients and methods: A nationwide cross-sectional survey with a two-stage cluster sampling was conducted from Oct. 2016 to Nov. 2017. Twenty-two of 54 total ART clinics representing >90% of the national cohort of adults on ART were included. HIVDR was assessed for protease and reverse transcriptase Sanger sequences using the Stanford HIVdb tool. Results: A total of 729 PLHIV were enrolled; 26.3% (95% CI 20.1%-33.5%) ART initiators reported prior exposure to antiretrovirals. Pre-treatment HIVDR prevalence was 26.9% (95% CI 20.2%-34.9%) to any antiretroviral and 25.9% (19.2%-33.9%) to NNRTIs. NNRTI pre-treatment HIVDR was higher in ART initiators with prior exposure to antiretrovirals (P = 0.001). Viral load (VL) suppression rate was 89.7% (85.1%-93.0%) in ADR12 and 67.9% (61.7%-73.6%) in ADR48. ADR12 to any drug among PLHIV with VL ≥1000 copies/mL was 86.1% (48.9%-97.6%); 67.1% (37.4%-87.5%) had HIVDR to both NNRTIs and NRTIs, and 3.8% (0.5%-25.2%) to PIs. ADR48 was 92.0% (86.8%-95.3%) to any drug; 78.1% (66.6%-86.5%) to both NNRTIs and NRTIs, and 7.3% (1.8%-25.1%) to PIs. Conclusions: The high prevalence of NNRTI pre-treatment HIVDR observed in Honduras warrants consideration of non-NNRTI-based first-line regimens for ART initiation. Programmatic improvements in HIVDR monitoring and adherence support may also be considered.
Journal of Antimicrobial Chemotherapy published new progress about Anti-HIV agents (anti-HIV-1 agents, anti-hiv-1 drugs). 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics